5-alpha reductase inhibitors (5-ARi) with or without alpha-blockers (α-B) for Benign Prostatic Hyperplasia do NOT lower the risk of incident Bladder Cancer: United States insurance claims data.

Francesco Del GiudiceFederico BelladelliFrank GloverSatvir BasranShufeng LiEvan MulloyBenjamin PradereFrancesco SoriaWojciech KrajewskiRajesh NairWade MunceyNicolas SeranioMichael L Eisenberg

Published in: World journal of urology (2023)

We did not find any diminished risk of new BCa in men treated with 5-ARi (i.e., chemoprotective effect). The current report suggests that 5-ARi do not change a man's bladder cancer risk.

Keyphrases

benign prostatic hyperplasia
lower urinary tract symptoms
health insurance
cardiovascular disease
spinal cord injury
affordable care act
big data
type diabetes
newly diagnosed
muscle invasive bladder cancer
angiotensin ii